Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 20/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3357263 | 1.00 | P2RX7 (0.73) | P2RX7 | |
| SCHEMBL30341755 | 1.00 | P2RX7 (0.73) | P2RX7 | |
| SCHEMBL6401708 | 0.89 | P2RX7 (0.72) | P2RX7 | |
| SCHEMBL6402297 | 0.89 | P2RX7 (0.57) | P2RX7 | |
| SCHEMBL6401712 | 0.89 | P2RX7 (0.72) | P2RX7 | |
| SCHEMBL6404367 | 0.89 | P2RX7 (0.57) | P2RX7 | |
| SCHEMBL6404281 | 0.89 | P2RX7 (0.57) | P2RX7 | |
| SCHEMBL6404370 | 0.89 | P2RX7 (0.57) | P2RX7 | |
| SCHEMBL6406819 | 0.88 | P2RX7 (0.72) | P2RX7 | |
| SCHEMBL6406309 | 0.88 | P2RX7 (0.72) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034213-A1 | SYSTEMS AND METHODS FOR TARGETING NAD-BASED PATHWAYS FOR TREATMENT OF CANCER | UNIV HONG KONG (CN) | 2026-02-05 | — | — | US | claimed |
| WO-2025229484-A1 | PURINERGIC P2 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF CONGENITAL SIDEROBLASTIC ANEMIAS | UNIVERSITÀ DEGLI STUDI DI BARI ALDO MORO (IT) | 2025-11-06 | — | — | WO | claimed |
| CN-119564861-A | Use of P2RX7 inhibitor for preparing medicine for preventing and treating peripheral nerve injury during chemotherapy | 南京中医药大学 | 2025-03-07 | — | — | CN | claimed |
| US-20130150410-A1 | Controlled Release Ion Channel Modulator Compositions and Methods for the Treatment of Otic Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-13 | — | — | US | claimed |
| US-20050171195-A1 | P2X7 antagonists for treating neuropathic pain | ABBOTT LABORATORIES | 2005-08-04 | — | — | US | claimed |
| WO-2026041663-A1 | P2X7 RECEPTOR ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2026-02-26 | — | — | WO | disclosed |
| US-20260034213-A1 | SYSTEMS AND METHODS FOR TARGETING NAD-BASED PATHWAYS FOR TREATMENT OF CANCER | UNIV HONG KONG (CN) | 2026-02-05 | — | — | US | disclosed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250367144-A1 | TREATMENT OF HYPERINFLAMMATORY SYNDROME | REMICINE IP B V (NL) | 2025-12-04 | — | — | US | disclosed |
| US-20250352663-A1 | Nanoclusters Functionalized with Adenosine Triphosphate or an Analogue and Their Use | UNIV LELAND STANFORD JUNIOR (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2025229484-A1 | PURINERGIC P2 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF CONGENITAL SIDEROBLASTIC ANEMIAS | UNIVERSITÀ DEGLI STUDI DI BARI ALDO MORO (IT) | 2025-11-06 | — | — | WO | disclosed |
| US-12419848-B2 | Treatment of hyperinflammatory syndrome | Remicine IP B.V. (NL) | 2025-09-23 | — | — | US | disclosed |
| EP-3919062-A1 | MODULATORS OF PURINERGIC RECEPTORS AND RELATED IMMUNE CHECKPOINT FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROM | Institut Gustave-Roussy (FR) | 2021-12-08 | — | — | EP | disclosed |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20190307678-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2019-10-10 | — | — | US | disclosed |
| US-10272034-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20160095902-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTONOMY, INC. | 2016-04-07 | — | — | US | disclosed |
| US-9132087-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20130150410-A1 | Controlled Release Ion Channel Modulator Compositions and Methods for the Treatment of Otic Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-13 | — | — | US | disclosed |
| US-20050171195-A1 | P2X7 antagonists for treating neuropathic pain | ABBOTT LABORATORIES | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171195-A1 | P2X7 antagonists for treating neuropathic pain | P2RX3, P2RX7, P2RX1 | P2RX7 2/4885 |
| US-20130150410-A1 | Controlled Release Ion Channel Modulator Compositions and Methods for the Treatment of Otic Disorders | TRPV1, ATP2A1, TRPM2 | P2RX7 196/4885 |
| US-20190307678-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | P2RX7 235/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | P2RX7 4082/4885 |
| US-20260034213-A1 | SYSTEMS AND METHODS FOR TARGETING NAD-BASED PATHWAYS FOR TREATMENT OF CANCER | NAMPT, NADK, CD274 | P2RX7 44/4885 |
| US-20160095902-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTC, AQP4, SLC26A4 | P2RX7 235/4885 |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTC, AQP4, SLC26A4 | P2RX7 235/4885 |
| US-10272034-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | P2RX7 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.